转移性-话题@MedSci

#转移性#

975篇内容 | 3337人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1386556, encodeId=b50413865569c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=JAMA Oncol：3期转移性去势抵抗前列腺癌临床试验中患者角度的副作用事件评估, objectType=article, longId=182314, objectId=2a7a18231406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7a18231406, replyNumber=0, likeNumber=68, createdTime=2019-11-05, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7a18231406, moduleTitle=JAMA Oncol：3期转移性去势抵抗前列腺癌临床试验中患者角度的副作用事件评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a7a18231406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386555, encodeId=03e2138655518, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：帕博西尼联合内分泌疗法治疗激素受体阳性、HER-2阴性的转移性乳腺癌, objectType=article, longId=182128, objectId=7074182128d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7074182128d0, replyNumber=0, likeNumber=79, createdTime=2019-10-31, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7074182128d0, moduleTitle=Lancet Oncol：帕博西尼联合内分泌疗法治疗激素受体阳性、HER-2阴性的转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7074182128d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386554, encodeId=b05e13865549c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Nature：转移性实体瘤的全癌全基因组分析, objectType=article, longId=181990, objectId=f9b318199032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9b318199032, replyNumber=0, likeNumber=77, createdTime=2019-10-28, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9b318199032, moduleTitle=Nature：转移性实体瘤的全癌全基因组分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9b318199032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386553, encodeId=58461386553aa, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Clin Chem：循环肿瘤细胞作为复发或转移性头颈部鳞状细胞癌的预后因素？, objectType=article, longId=181846, objectId=37b0181846f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37b0181846f1, replyNumber=0, likeNumber=81, createdTime=2019-10-25, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37b0181846f1, moduleTitle=Clin Chem：循环肿瘤细胞作为复发或转移性头颈部鳞状细胞癌的预后因素？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37b0181846f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386552, encodeId=fec813865520c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据, objectType=article, longId=181811, objectId=3a1a18181105, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a1a18181105, replyNumber=0, likeNumber=49, createdTime=2019-10-25, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a1a18181105, moduleTitle=MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a1a18181105)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386551, encodeId=112013865512b, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=靶向HER2的抗体偶联药物ADC治疗转移性乳腺癌获得FDA的优先审查, objectType=article, longId=181781, objectId=1e9c181e813c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e9c181e813c, replyNumber=0, likeNumber=69, createdTime=2019-10-24, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e9c181e813c, moduleTitle=靶向HER2的抗体偶联药物ADC治疗转移性乳腺癌获得FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e9c181e813c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386550, encodeId=50d91386550d5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Seattle Genetics的酪氨酸激酶抑制剂tucatinib治疗晚期或转移性乳腺癌临床试验成功, objectType=article, longId=181705, objectId=c214181e05e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c214181e05e3, replyNumber=0, likeNumber=65, createdTime=2019-10-23, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c214181e05e3, moduleTitle=Seattle Genetics的酪氨酸激酶抑制剂tucatinib治疗晚期或转移性乳腺癌临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c214181e05e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386549, encodeId=d92813865499f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：绝经后HR+/HER2-转移性乳腺癌一线或二线治疗——内分泌为基础治疗较化疗更优, objectType=article, longId=181205, objectId=bec7181205bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec7181205bb, replyNumber=0, likeNumber=68, createdTime=2019-10-16, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec7181205bb, moduleTitle=Lancet Oncol：绝经后HR+/HER2-转移性乳腺癌一线或二线治疗——内分泌为基础治疗较化疗更优, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bec7181205bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386548, encodeId=4dc91386548bc, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet Oncol：埃罗替尼+雷莫芦单抗治疗EGFR突变型转移性NSCLC, objectType=article, longId=180839, objectId=78aa180839bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78aa180839bf, replyNumber=0, likeNumber=86, createdTime=2019-10-11, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78aa180839bf, moduleTitle=Lancet Oncol：埃罗替尼+雷莫芦单抗治疗EGFR突变型转移性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78aa180839bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386547, encodeId=447b138654e1f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=JAMA Oncol：紫杉醇、吉西他滨以及顺铂治疗转移性胰腺癌, objectType=article, longId=180724, objectId=1d0c180e24c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d0c180e24c3, replyNumber=0, likeNumber=103, createdTime=2019-10-10, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d0c180e24c3, moduleTitle=JAMA Oncol：紫杉醇、吉西他滨以及顺铂治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d0c180e24c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386546, encodeId=496b1386546fd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=单抗联合化疗治疗复发转移性膀胱尿路上皮癌患者获益明确, objectType=article, longId=180693, objectId=99e0180693c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99e0180693c9, replyNumber=0, likeNumber=93, createdTime=2019-10-10, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99e0180693c9, moduleTitle=单抗联合化疗治疗复发转移性膀胱尿路上皮癌患者获益明确, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99e0180693c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386545, encodeId=8eb613865450c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=SCO-101治疗转移性结直肠癌患者的II期临床试验已开始, objectType=article, longId=180576, objectId=5f001805e6d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f001805e6d8, replyNumber=0, likeNumber=93, createdTime=2019-10-07, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f001805e6d8, moduleTitle=SCO-101治疗转移性结直肠癌患者的II期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f001805e6d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386544, encodeId=2a6913865447a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, objectType=article, longId=180512, objectId=112b180512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112b180512c6, replyNumber=0, likeNumber=68, createdTime=2019-10-06, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112b180512c6, moduleTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=112b180512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386543, encodeId=ba87138654337, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=2019 ESMO：Arfolitixorin治疗转移性结直肠癌的全球III期研究, objectType=article, longId=180370, objectId=a2be1803e048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2be1803e048, replyNumber=0, likeNumber=105, createdTime=2019-10-02, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2be1803e048, moduleTitle=2019 ESMO：Arfolitixorin治疗转移性结直肠癌的全球III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2be1803e048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386542, encodeId=b66b1386542d4, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗, objectType=article, longId=180183, objectId=e8d718018362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8d718018362, replyNumber=0, likeNumber=80, createdTime=2019-09-29, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8d718018362, moduleTitle=NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8d718018362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386541, encodeId=6ab4138654136, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, objectType=article, longId=179755, objectId=246d1e9755d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=246d1e9755d6, replyNumber=0, likeNumber=81, createdTime=2019-09-21, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=246d1e9755d6, moduleTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=246d1e9755d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386540, encodeId=32ea1386540d2, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=强生的雄激素受体抑制剂Erleada获得FDA批准，治疗转移性去势敏感性前列腺癌, objectType=article, longId=179672, objectId=33491e967221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33491e967221, replyNumber=0, likeNumber=80, createdTime=2019-09-20, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33491e967221, moduleTitle=强生的雄激素受体抑制剂Erleada获得FDA批准，治疗转移性去势敏感性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33491e967221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386539, encodeId=fa3f13865398c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查, objectType=article, longId=179625, objectId=df171e962513, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df171e962513, replyNumber=0, likeNumber=78, createdTime=2019-09-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df171e962513, moduleTitle=Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df171e962513)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386538, encodeId=ce361386538e9, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet oncol：卡巴他赛联合卡铂治疗去雄耐受性的转移性前列腺癌, objectType=article, longId=179257, objectId=a1d11e925723, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1d11e925723, replyNumber=0, likeNumber=85, createdTime=2019-09-12, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1d11e925723, moduleTitle=Lancet oncol：卡巴他赛联合卡铂治疗去雄耐受性的转移性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1d11e925723)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386537, encodeId=8a4f138653e23, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Gastric Cancer：低蛋白血症可以预测转移性胃癌患者的静脉血栓栓塞风险, objectType=article, longId=179120, objectId=29d01e91205f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29d01e91205f, replyNumber=0, likeNumber=83, createdTime=2019-09-10, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29d01e91205f, moduleTitle=Gastric Cancer：低蛋白血症可以预测转移性胃癌患者的静脉血栓栓塞风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29d01e91205f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性

2020-05-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

JAMA Oncol：3期转移性去势抵抗前列腺癌临床试验中患者角度的副作用事件评估

2019-11-05

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Oncol：帕博西尼联合内分泌疗法治疗激素受体阳性、HER-2阴性的转移性乳腺癌

2019-10-31

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Nature：转移性实体瘤的全癌全基因组分析

2019-10-28

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Clin Chem：循环肿瘤细胞作为复发或转移性头颈部鳞状细胞癌的预后因素？

2019-10-25

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

MacroGenics宣布HER2单抗Margetuximab在转移性乳腺癌患者中的III期临床SOPHIA的第二次总体中期生存数据

2019-10-25

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

靶向HER2的抗体偶联药物ADC治疗转移性乳腺癌获得FDA的优先审查

2019-10-24

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Seattle Genetics的酪氨酸激酶抑制剂tucatinib治疗晚期或转移性乳腺癌临床试验成功

2019-10-23

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Oncol：绝经后HR+/HER2-转移性乳腺癌一线或二线治疗——内分泌为基础治疗较化疗更优

2019-10-16

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet Oncol：埃罗替尼+雷莫芦单抗治疗EGFR突变型转移性NSCLC

2019-10-11

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

JAMA Oncol：紫杉醇、吉西他滨以及顺铂治疗转移性胰腺癌

2019-10-10

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

单抗联合化疗治疗复发转移性膀胱尿路上皮癌患者获益明确

2019-10-10

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

SCO-101治疗转移性结直肠癌患者的II期临床试验已开始

2019-10-07

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定

2019-10-06

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

2019 ESMO：Arfolitixorin治疗转移性结直肠癌的全球III期研究

2019-10-02

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗

2019-09-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019

2019-09-21

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

强生的雄激素受体抑制剂Erleada获得FDA批准，治疗转移性去势敏感性前列腺癌

2019-09-20

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查

2019-09-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet oncol：卡巴他赛联合卡铂治疗去雄耐受性的转移性前列腺癌

2019-09-12

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Gastric Cancer：低蛋白血症可以预测转移性胃癌患者的静脉血栓栓塞风险

2019-09-10

科室
- - 订阅+
  - 更多科室
工具
服务